Domantis First To Win UK Innovation In Drug Discovery & Development Award

Domantis is the first winner of the UK Innovation in Drug Discovery & Development Award, one of three new BioEntrepreneur Awards sponsored by London First and UK Trade & Investment.

The award recognises Domantis’ contribution to the UK’s dominant position in the development of innovative medicine.

Executive VP and CSO Dr. Ian Tomlinson said, "I am delighted to receive this award which highlights Domantis’ pioneering approach to developing novel therapeutics based on human Domain Antibodies.”

“Domantis is currently building a rich pipeline of novel dAb medicines to combat disorders such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis (RA) and cancer.”

The two other finalists were Powdermed and Spirogen.

Domantis Limited

Domantis Limited
Drug discovery platform



DownloadFull Press Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera